Stocks & Investing
Stocks and Investing
Stocks and Investing
Wed, August 16, 2023
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Keay Nakae Maintained (SONN) at Strong Buy on, Aug 16th, 2023
Keay Nakae of Chardan Capital, Maintained "Sonnet BioTherapeutics Holdings, Inc." (SONN) at Strong Buy on, Aug 16th, 2023.
Keay has made no other calls on SONN in the last 4 months.
There is 1 other peer that has a rating on SONN. Out of the 1 peers that are also analyzing SONN, 0 agree with Keay's Rating of Hold.
This is the rating of the analyst that currently disagrees with Keay
- Michael King of "EF Hutton" Reiterated at Strong Buy on, Monday, June 26th, 2023
